DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2010/0286160 A1 Gilbert Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

US 2010O286160A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0286160 A1 Gilbert et al. (43) Pub. Date: Nov. 11, 2010 (54) SUBSTITUTED PIPERAZINES AS CB1 Related U.S. Application Data ANTAGONSTS (60) Provisional application No. 60/946,896, filed on Jun. (75) Inventors: Eric J. Gilbert, Scotch Plains, NJ 28, 2007. (US); William J. Greenlee, Teaneck, NJ (US); Sarah Wei Li, Publication Classification Belle Mead, NJ (US); Michael W. (51) Int. Cl. Miller, Scotch Plains, NJ (US); A 6LX 3L/2197 (2006.01) Jack D. Scott, Scotch Plains, NJ C07D 24I/04 (2006.01) (US); Adrew Stamford, Chatham C07D 403/2 (2006.01) Township, NJ (US); Chander C07D 24I/02 (2006.01) Shekher Celly, Colonia, NJ (US) C07D 40/12 (2006.01) C07D 40/4 (2006.01) Correspondence Address: A6IP 9/00 (2006.01) MERCK PATENT DEPARTMENT (K-6-1, 1990) (52) U.S. Cl. .................... 514/252.11:544/400: 544/372: 2000 GALLOPNGHILL ROAD 544/370; 544/357: 514/254.01: 514/254.05; KENILWORTH, NJ 07033-0530 (US) 514/252.12:544/360; 514/253.13:544/364; 514/253.09 (73) Assignee: Intervet Inc. (57) ABSTRACT (21) Appl. No.: 12/665,253 Compounds of Formula (I): or pharmaceutically acceptable (22) PCT Fled: Jun. 25, 2008 salts, Solvates, oresters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic (86) PCT NO.: PCT/US08/07917 syndrome and obesity, neuroinflammatory disorders, cogni tive disorders and psychosis, addiction (e.g., Smoking cessa S371 (c)(1), tion), gastrointestinal disorders, and cardiovascular condi (2), (4) Date: Jun. 14, 2010 tions. US 2010/0286160 A1 Nov. 11, 2010 SUBSTITUTED PPERAZINES AS CB1 0006 CB (CB-/-) and CB (CB-/-) receptor knockout ANTAGONSTS mice have been used to elucidate the specific role of the two cannabinoid receptor Subtypes. Furthermore, for ligands Such PRIORAPPLICATIONS as delta-9-THC which act as agonists at both receptors, these mice have allowed identification of which receptor subtype is 0001. This application claims the benefit of priority to mediating specific physiological effects. CB-/-, but not Application No. 60/946,896, filed Jun. 28, 2007, which is CB-/-, mice are resistant to the behavioural effects of ago incorporated in its entirety by reference. nists such as delta-9-THC. CB-/- animals have also been shown to be resistant to both the body weight gain associated BACKGROUND OF THE INVENTION with chronic high fat diet exposure, and the appetite-stimu lating effects of acute food deprivation. 0002 The CB receptor is one of the most abundant neu 0007. These findings suggest a clear role for both endog romodulatory receptors in the brain, and is expressed at high enous and exogenous cannabinoid receptor agonists in levels in the hippocampus, cortex, cerebellum, and basal gan increasing food intake and body weight via selective activa glia (e.g., Wilson et al., Science, 2002, vol. 296, 678-682). tion of the CB receptor subtype. Selective CB receptor antagonists, for example pyrazole 0008. The therapeutic potential for cannabinoid receptor derivatives such as rimonabant (e.g., U.S. Pat. No. 6,432, ligands has been extensively reviewed (Exp. Opin. Ther. Pat. 984), can be used to treat various conditions, such as obesity and metabolic syndrome (e.g., Bensaid et al., Molecular 1998, 8,301-313; Exp. Opin. Ther. Pat. 2000, 10, 1529-1538; Pharmacology, 2003 vol. 63, no. 4, pp. 908-914: Trillou et al., Trends in Pharm. Sci. 2000, 21, 218-224: Exp. Opin. Ther. Am. J. Physiol. Regul. Integr: Comp. Physiol. 2002 vol. 284, Pat. 2002, 12(10), 1475-1489). R345-R353; Kirkham, Am. J. Physiol. Regul. Integr: Comp. 0009. At least one compound (SR-14171 6A: Rimona Physiol. 2002 vol. 284, R343-R344), neuroinflammatory dis bant) characterised as a CB receptor antagonist/inverse ago orders (e.g., Adam, et al., Expert Opin. Ther. Patents, 2002, nist is known to be in clinical trials for the treatment of vol. 12, no. 10, 1475-1489; U.S. Pat. No. 6,642,258), cogni obesity. tive disorders and psychosis (e.g., Adam et al., Expert Opin. 0010 Clinical trials with the CB receptor antagonist Ther. Pat., 2002, vol. 12, pp. 1475-1489), addiction (e.g., rimonabant have also observed an antidiabetic action that smoking cessation; U.S. Patent Publ. 2003/0087933), gas exceeds that accounted for by weight loss alone (Scheen A.J., trointestinal disorders (e.g., Lange et al., J. Med. Chem. 2004, et al., Lancet, 2006 in press). CB receptor mRNA is located vol. 47, 627-643) and cardiovascular conditions (e.g., Porter on C- and B-cells in the Islets of Langerhans and it has been et al., Pharmacology and Therapeutics, 2001 Vol. 90, 45-60; reported that CB receptor agonists reduce insulin release Sanofi-Aventis Publication, Bear Stearns Conference, New from pancreatic beta cells in vitro in response to a glucose York, Sep. 14, 2004, pages 19-24). There now exists extensive load (Juan-Pico et al. Cell Calcium, 39, (2006), 155-162). pre-clinical and clinical data Supporting the use of CB1 recep Consistent with this, Bermudez-Siva et al., (Eur J. Pharma tor antagonists/inverse agonists for the treatment of obesity. col., 531 (2006), 282-284) have reported that CB receptor 0003 Preparations of marijuana (Cannabis sativa) have agonists increase glucose intolerance following ip injection been used for over 5000 years for both medicinal and recre of a glucose load to rats. This effect was reversed by a CB ational purposes. The major psychoactive ingredient of mari receptorantagonist that increased glucose tolerance in the test juana has been identified as delta-9-tetrahydrocannabinol when given alone. Thus, the action of rimonabant may be due (delta-9-THC), one of a member of over 60 related cannab to a direct action on the pancreas. It is also possible that CB inoid compounds isolated from this plant. It has been dem receptor antagonists affect insulin sensitivity indirectly via an onstrated that delta-9-THC exerts its effects via agonist inter action on adiponectin (Chandran et al., Diabetes care, 26. action with cannabinoid (CB) receptors. So far, two (2003), 2442-2450) which is elevated by CB receptor cannabinoid receptor subtypes have been characterised (CB antagonists (Cota et al., J. Clin Invest., 112 (2003), 423-431; and CB). The CB receptor subtype is found predominantly Bensaid et al., Mol. Pharmacol., 63 (2003, 908-914). Indeed, in the central nervous system, and to a lesser extent in the it has been reported that endocannabinoid levels are enhanced peripheral nervous system and various peripheral organs. The in the pancreas and adipose tissue of obese and diabetic mice CB receptor Subtype is found predominantly in lymphoid and in the plasma and adipose tissue of obese or type 2 tissues and cells. To date, three endogenous agonists (en diabetic patients (Matias et al., JClin Endocrinol and Metab., docannabinoids) have been identified which interact with 91 (2006), 3171-3180) suggesting a possible causal role of both CB and CB receptors (anandamide, 2-arachidonyl elevated cannabinoid tone in the onset of type 2 diabetes. glycerol and noladin ether). 0011. However, there is still a need for improved cannab 0004 Genetically obese rats and mice exhibit markedly inoid agents, particularly selective CB receptor antagonists, elevated endocannabinoid levels in brain regions associated with fewer side-effects and improved efficacy. with ingestive behaviour (DiMarzo et al. 2001 Nature 410: 0012 WO95/25443, U.S. Pat. No. 5,464,788, and U.S. 822-825). Furthermore, increased levels of endocannab Pat. No. 5,756,504 describe N-arylpiperazine compounds inoids are observed upon the fasting of normal, lean animals useful for treating preterm labor, stopping labor, and dysmen (Kirkham et al., British Journal of Pharmacology 2002, 136 orrhea. However, none of the N-aryl piperazines exemplified (4) 550-557). therein have an aryland/or heteroaryl substituent at both the 0005 Exogenous application of endocannabinoids leads 1- and 2-positions of the piperazine ring. to the same physiological effects observed with delta-9-THC (0013 WO 01/02372 and U.S. Published Application No. treatment, including appetite stimulation (Jamshida et al., 2003/0186960 describe cyclized amino acid derivatives for British Journal of Pharmacology 2001, 134: 1151-1 154), treating or preventing neuronal damage associated with neu analgesia, hypolocomotion, hypothermia, and catalepsy. rological diseases. However, none of the 3-aryl piperazine US 2010/0286160 A1 Nov. 11, 2010 2-ones exemplified therein have an aryl and/or heteroaryl compounds disclosed have a Substituted aryl and/or het substituent at both the 1- and 2-positions of the piperazine eroaryl Substituent at both the 1- and 2-positions of a pipera ring. Zine ring. 0014 WO 96/01656 describes radiolabelled substituted (0024 WO 2007/020502 describes pyrrolidone com piperazines useful in pharmacological screening procedures, pounds as cannabinoid receptor ligands, in particular CB1 receptor ligands, and their use intreating diseases, conditions, including labeled N-aryl piperazines. However, none of the and/or disorders modulated by cannabinoid receptor antago N-aryl piperazines exemplified therein have an aryl and/or nists. However, none of the compounds disclosed have a heteroaryl substituent at both the 1- and 2-positions of the substituted aryl and/or heteroaryl substituent at both the 1 piperazine ring. and 2-positions of a piperazine ring. 0015 U.S. Pat. No. 5,780,480 describes N-aryl pipera 0025 WO 2007/057687 and WO2006/060461 describe Zines useful as fibrinogen receptor antagonists for inhibiting piperazine derivatives and their use as CB1 antagonists and in the binding offibrinogen to blood platelets, and for inhibiting treating various diseases, conditions, and/or disorders modu the aggregation of blood platelets. However, none of the lated by cannabinoid receptor antagonists.
Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al

    (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al

    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
  • Specifications of Approved Drug Compound Library

    Specifications of Approved Drug Compound Library

    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
  • (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al

    (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis Et Al

    USOO7803838B2 (12) United States Patent (10) Patent No.: US 7.803,838 B2 Davis et al. (45) Date of Patent: Sep. 28, 2010 (54) COMPOSITIONS COMPRISING NEBIVOLOL 2002fO169134 A1 11/2002 Davis 2002/0177586 A1 11/2002 Egan et al. (75) Inventors: Eric Davis, Morgantown, WV (US); 2002/0183305 A1 12/2002 Davis et al. John O'Donnell, Morgantown, WV 2002/0183317 A1 12/2002 Wagle et al. (US); Peter Bottini, Morgantown, WV 2002/0183365 A1 12/2002 Wagle et al. (US) 2002/0192203 A1 12, 2002 Cho 2003, OOO4194 A1 1, 2003 Gall (73) Assignee: Forest Laboratories Holdings Limited 2003, OO13699 A1 1/2003 Davis et al. (BM) 2003/0027820 A1 2, 2003 Gall (*) Notice: Subject to any disclaimer, the term of this 2003.0053981 A1 3/2003 Davis et al. patent is extended or adjusted under 35 2003, OO60489 A1 3/2003 Buckingham U.S.C. 154(b) by 455 days. 2003, OO69221 A1 4/2003 Kosoglou et al. 2003/0078190 A1* 4/2003 Weinberg ...................... 514f1 (21) Appl. No.: 11/141,235 2003/0078517 A1 4/2003 Kensey 2003/01 19428 A1 6/2003 Davis et al. (22) Filed: May 31, 2005 2003/01 19757 A1 6/2003 Davis 2003/01 19796 A1 6/2003 Strony (65) Prior Publication Data 2003.01.19808 A1 6/2003 LeBeaut et al. US 2005/027281.0 A1 Dec. 8, 2005 2003.01.19809 A1 6/2003 Davis 2003,0162824 A1 8, 2003 Krul Related U.S. Application Data 2003/0175344 A1 9, 2003 Waldet al. (60) Provisional application No. 60/577,423, filed on Jun.
  • Role of Proaggregatory and Antiaggregatory Prostaglandins in Hemostasis

    Role of Proaggregatory and Antiaggregatory Prostaglandins in Hemostasis

    Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism. P Gresele, … , G Pieters, J Vermylen J Clin Invest. 1987;80(5):1435-1445. https://doi.org/10.1172/JCI113223. Research Article Thromboxane synthase inhibition can lead to two opposing effects: accumulation of proaggregatory cyclic endoperoxides and increased formation of antiaggregatory PGI2 and PGD2. The elimination of the effects of the cyclic endoperoxides by an endoperoxide-thromboxane A2 receptor antagonist should enhance the inhibition of hemostasis by thromboxane synthase blockers. We have carried out a series of double-blind, placebo-controlled, crossover studies in healthy volunteers to check if this hypothesis may be operative in vivo in man. In a first study, in 10 healthy male volunteers, the combined administration of the thromboxane receptor antagonist BM 13.177 and the thromboxane synthase inhibitor dazoxiben gave stronger inhibition of platelet aggregation and prolonged the bleeding time more than either drug alone. In a second study, in 10 different healthy male volunteers, complete inhibition of cyclooxygenase with indomethacin reduced the prolongation of the bleeding time by the combination BM 13.177 plus dazoxiben. In a third study, in five volunteers, selective cumulative inhibition of platelet TXA2 synthesis by low-dose aspirin inhibited platelet aggregation and prolonged the bleeding time less than the combination BM 13.177 plus dazoxiben. In vitro, in
  • Aggressive Imaging in Young Children on Antithrombotic Therapy With

    Aggressive Imaging in Young Children on Antithrombotic Therapy With

    American Journal of Emergency Medicine 37 (2019) 972–1004 Contents lists available at ScienceDirect American Journal of Emergency Medicine journal homepage: www.elsevier.com/locate/ajem Correspondence Aggressive imaging in young children on Low molecular weight heparin (LMWH) is the most commonly used antithrombotic therapy with minor traumatic drug for acute VTE in pediatric patients [12,13]. A review reported of head injury 308 children receiving therapeutic doses LMWH for the treated of VTE, nine (2.9%) had a major bleeding, and 72 (23.4%) a minor bleeding Clinical decision rules have been developed to guide clinicians to [14]. In 133 children receiving prophylactic doses of LMWH, one (0.8%) perform or to omit a CT scan in children with minor traumatic head in- had a major bleeding, and four (3.0%) a minor bleeding. These bleedings jury (MTHI) [1-3]. These guidelines do not define the use of antithrom- occurred all spontaneously without a traumatic cause. Vitamin K antag- botic therapy as a major risk factor for intracranial pathology in young onists (VKA) include warfarin, acenocoumarol and phenprocoumon. children, in contrast to children of six years and older and adults, The most common VKA used in the pediatric setting is warfarin [13]. where this is an indication to perform a CT scan. Risk of major bleeding varies including 0.5% per patient year reported A two-year-old boy on antithrombotic treatment fell on the back of in a large cohort study versus 12.2% in a randomized controlled trial of his head from a one-meter high slide.
  • Effect of Prostanoids on Human Platelet Function: an Overview

    Effect of Prostanoids on Human Platelet Function: an Overview

    International Journal of Molecular Sciences Review Effect of Prostanoids on Human Platelet Function: An Overview Steffen Braune, Jan-Heiner Küpper and Friedrich Jung * Institute of Biotechnology, Molecular Cell Biology, Brandenburg University of Technology, 01968 Senftenberg, Germany; steff[email protected] (S.B.); [email protected] (J.-H.K.) * Correspondence: [email protected] Received: 23 October 2020; Accepted: 23 November 2020; Published: 27 November 2020 Abstract: Prostanoids are bioactive lipid mediators and take part in many physiological and pathophysiological processes in practically every organ, tissue and cell, including the vascular, renal, gastrointestinal and reproductive systems. In this review, we focus on their influence on platelets, which are key elements in thrombosis and hemostasis. The function of platelets is influenced by mediators in the blood and the vascular wall. Activated platelets aggregate and release bioactive substances, thereby activating further neighbored platelets, which finally can lead to the formation of thrombi. Prostanoids regulate the function of blood platelets by both activating or inhibiting and so are involved in hemostasis. Each prostanoid has a unique activity profile and, thus, a specific profile of action. This article reviews the effects of the following prostanoids: prostaglandin-D2 (PGD2), prostaglandin-E1, -E2 and E3 (PGE1, PGE2, PGE3), prostaglandin F2α (PGF2α), prostacyclin (PGI2) and thromboxane-A2 (TXA2) on platelet activation and aggregation via their respective receptors. Keywords: prostacyclin; thromboxane; prostaglandin; platelets 1. Introduction Hemostasis is a complex process that requires the interplay of multiple physiological pathways. Cellular and molecular mechanisms interact to stop bleedings of injured blood vessels or to seal denuded sub-endothelium with localized clot formation (Figure1).
  • Statistical Analysis Plan – Part 1

    Statistical Analysis Plan – Part 1

    NCT03251482 Janssen Research & Development Statistical Analysis Plan – Part 1 A Randomized, Double-blind, Double-dummy, Multicenter, Adaptive Design, Dose Escalation (Part 1) and Dose-Response (Part 2) Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Subjects Undergoing Elective Total Knee Replacement Surgery Protocol 64179375THR2001; Phase 2 JNJ-64179375 Status: Approved Date: 18 October 2017 Prepared by: Janssen Research & Development, LLC Document No.: EDMS-ERI-148215770 Compliance: The study described in this report was performed according to the principles of Good Clinical Practice (GCP). Confidentiality Statement The information in this document contains trade secrets and commercial information that are privileged or confidential and may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as privileged or confidential. 1 Approved, Date: 18 October 2017 JNJ-64179375 NCT03251482 Statistical Analysis Plan - Part 1 64179375THR2001 TABLE OF CONTENTS TABLE OF CONTENTS ............................................................................................................................... 2 LIST OF IN-TEXT TABLES AND FIGURES ...............................................................................................
  • Acute Necrotizing Pancreatitis in Rats

    Acute Necrotizing Pancreatitis in Rats

    ACUTE NECROTIZING PANCREATITIS IN RATS Acute necrotizerende pancreatitis in ratten PROEFSCHRIFT TER VERKRIJGING VAN DE GRAAD VAN DOCTOR IN DE GENEESKUNDE AAN DE ERASMUS UNIVERSITEIT ROTTERDAM OP GEZAG VAN DE RECTOR MAGNIFICUS PROF. DR. A.H.G. RINNOOY KAN EN VOLGENS BESLUIT VAN HET COLLEGE VAN DEKANEN. DE OPENBARE VERDEDIGING ZAL PLAATSVINDEN OP VRIJDAG 22 JANUARI 1988 TE 15.45 UUR door BAAN VAN OOIJEN geboren te Rotterdam Druk: Krips Repro Meppel 1987 PROMOTIECOMMISSIE PROMOTOREN PROF. J.H.P. WILSON PROF. DR. J. JEEKEL OVERIGE LEDEN: PROF. DR. I.L. BONTA PROF. DR. J.L. TERPSTRA 1987 B. van Ooijen No part of this book may be reproduced in any form, by print, photoprint, microfilm or any other means without written permission from the publisher. De druk van dit proefschrift werd mede mogelijk gemaakt door financiele steun van het Bronovo Researchfonds. Wat heb ik dat ik niet gekregen heb? aJNTENTS page ABBREVIATIONS CHAPTER 1: INTRODUCTION AND AIM OF THE STUDY. 1 1.1. References 3 CHAPTH• 2: ETIOLOGICAL FACTORS IN ACUTE PANCREATITIS. 2. 1. Introduction 4 2.2. Etiological factors 5 2.2.1. Mechanical block at ampulla 6 a. Biliary tract disease 6 a-1. Bile reflux 7 a-2. Pancreatic duct obstruction 8 b. Obstruction at the level of the ampulla 8 b-1. Pancreas divisum 9 c. Duodenal disorders 9 2.2.2. Vascular factors and ischemia 9 2.2.3. Toxic and metabolic factors 10 a. Alcoholism 10 b. Hypercalcemia 11 c. Hypertriglyceridemia 12 d. Other metabolic causes 12 e. Drugs 12 2.2.4. Infection 13 2.2.5.
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances

    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC
  • Study Protocol

    Study Protocol

    Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Synopsis Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Assess the Safety and Efficacy of ART-123 in Subjects with Severe Sepsis and Coagulopathy Name of Sponsor/Company: Asahi Kasei Pharma America Corporation Name of Investigational Product: ART-123 Name of Active Ingredient: thrombomodulin alpha Objectives Primary: x To evaluate whether ART-123, when administered to subjects with bacterial infection complicated by at least one organ dysfunction and coagulopathy, can reduce mortality. x To evaluate the safety of ART-123 in this population. Secondary: x Assessment of the efficacy of ART-123 in resolution of organ dysfunction in this population. x Assessment of anti-drug antibody development in subjects with coagulopathy due to bacterial infection treated with ART-123. Study Center(s): Phase of Development: Global study, up to 350 study centers Phase 3 Study Period: Estimated time of first subject enrollment: 3Q 2012 Estimated time of last subject enrollment: 3Q 2018 Number of Subjects (planned): Approximately 800 randomized subjects. Page 2 of 116 Protocol 3-001 Confidential 28APRIL2017 Version 4.1 Asahi Kasei Pharma America Corporation Diagnosis and Main Criteria for Inclusion of Study Subjects: This study targets critically ill subjects with severe sepsis requiring the level of care that is normally associated with treatment in an intensive care unit (ICU) setting. The inclusion criteria for organ dysfunction and coagulopathy must be met within a 24 hour period. 1. Subjects must be receiving treatment in an ICU or in an acute care setting (e.g., Emergency Room, Recovery Room).
  • Pharmaceutical Appendix to the Tariff Schedule 2

    Pharmaceutical Appendix to the Tariff Schedule 2

    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9